New Jersey

What state-level totals can and cannot tell you

The aggregate payment figure for any individual state should be read as a measurement of total reportable industry-physician engagement within that state's geographic footprint during the most recent program year, not as a measurement of any one physician's or institution's relationship with industry. The Centers for Medicare and Medicaid Services collects this data under the Physician Payments Sunshine Act, and applicable manufacturers and group purchasing organizations are required by federal law to report transfers of value above the de minimis threshold. The dataset is comprehensive across the reporting universe, but it does not capture every form of pharma-related spending — direct-to-consumer advertising, internal research-and-development expense, wholesale-drug pricing, and provider salary support that does not constitute a reportable transfer-of-value are all measured elsewhere.

The relationship between aggregate state payment volume and any policy-relevant outcome — prescribing patterns, prescription costs, patient outcomes, or specialty-mix decisions — is an active area of academic research. Studies routinely find statistically significant correlations between payment receipt and prescribing volume for specific drugs and specific physician populations, but the dataset does not establish causation in either direction. Some physicians may prescribe more of a manufacturer's drug because they have been engaged through speaker bureaus or consulting relationships; equally, manufacturers may target their engagement at physicians who were already prescribing or were predisposed to prescribe their drugs. The Open Payments dataset enables researchers to ask these questions but does not answer them on its own.